110 related articles for article (PubMed ID: 18782589)
1. Comparisons of RNAi approaches for validation of human RNA helicase A as an essential factor in hepatitis C virus replication.
He QS; Tang H; Zhang J; Truong K; Wong-Staal F; Zhou D
J Virol Methods; 2008 Dec; 154(1-2):216-9. PubMed ID: 18782589
[TBL] [Abstract][Full Text] [Related]
2. DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication.
Ariumi Y; Kuroki M; Abe K; Dansako H; Ikeda M; Wakita T; Kato N
J Virol; 2007 Dec; 81(24):13922-6. PubMed ID: 17855521
[TBL] [Abstract][Full Text] [Related]
3. Interfering with hepatitis C virus RNA replication.
Randall G; Rice CM
Virus Res; 2004 Jun; 102(1):19-25. PubMed ID: 15068876
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of hepatitis C virus replication and expression by small interfering RNA targeting host cellular genes.
Xue Q; Ding H; Liu M; Zhao P; Gao J; Ren H; Liu Y; Qi ZT
Arch Virol; 2007; 152(5):955-62. PubMed ID: 17273891
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus.
Zhang J; Yamada O; Sakamoto T; Yoshida H; Iwai T; Matsushita Y; Shimamura H; Araki H; Shimotohno K
Virology; 2004 Mar; 320(1):135-43. PubMed ID: 15003869
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of intracellular inhibition of hepatitis C virus replication by small interfering RNAs.
Chang B; Lee CH; Lee JH; Lee SW
Biotechnol Lett; 2010 Sep; 32(9):1231-7. PubMed ID: 20464448
[TBL] [Abstract][Full Text] [Related]
7. Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype.
Watanabe T; Sudoh M; Miyagishi M; Akashi H; Arai M; Inoue K; Taira K; Yoshiba M; Kohara M
Gene Ther; 2006 Jun; 13(11):883-92. PubMed ID: 16496015
[TBL] [Abstract][Full Text] [Related]
8. Potential applications of siRNA in hepatitis C virus therapy.
Smolic R; Volarevic M; Wu CH; Wu GY
Curr Opin Investig Drugs; 2006 Feb; 7(2):142-6. PubMed ID: 16499284
[TBL] [Abstract][Full Text] [Related]
9. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi).
Pan Q; Ramakrishnaiah V; Henry S; Fouraschen S; de Ruiter PE; Kwekkeboom J; Tilanus HW; Janssen HL; van der Laan LJ
Gut; 2012 Sep; 61(9):1330-9. PubMed ID: 22198713
[TBL] [Abstract][Full Text] [Related]
10. Multiple cyclophilins involved in different cellular pathways mediate HCV replication.
Gaither LA; Borawski J; Anderson LJ; Balabanis KA; Devay P; Joberty G; Rau C; Schirle M; Bouwmeester T; Mickanin C; Zhao S; Vickers C; Lee L; Deng G; Baryza J; Fujimoto RA; Lin K; Compton T; Wiedmann B
Virology; 2010 Feb; 397(1):43-55. PubMed ID: 19932913
[TBL] [Abstract][Full Text] [Related]
11. TAT peptides mediated small interfering RNA delivery to Huh-7 cells and efficiently inhibited hepatitis C virus RNA replication.
Meng S; Wei B; Xu R; Zhang K; Wang L; Zhang R; Li J
Intervirology; 2009; 52(3):135-40. PubMed ID: 19478527
[TBL] [Abstract][Full Text] [Related]
12. RNAi expression mediated inhibition of HCV replication.
Hamazaki H; Ujino S; Abe E; Miyano-Kurosaki N; Shimotohno K; Takaku H
Nucleic Acids Symp Ser (Oxf); 2004; (48):307-8. PubMed ID: 17150601
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response.
Wang Y; Kato N; Jazag A; Dharel N; Otsuka M; Taniguchi H; Kawabe T; Omata M
Gastroenterology; 2006 Mar; 130(3):883-92. PubMed ID: 16530526
[TBL] [Abstract][Full Text] [Related]
14. HCV core protein interacts with Dicer to antagonize RNA silencing.
Chen W; Zhang Z; Chen J; Zhang J; Zhang J; Wu Y; Huang Y; Cai X; Huang A
Virus Res; 2008 May; 133(2):250-8. PubMed ID: 18325616
[TBL] [Abstract][Full Text] [Related]
15. Potential role of RNAi in the treatment of HCV infection.
Volarevic M; Smolic R; Wu CH; Wu GY
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):823-31. PubMed ID: 17914916
[TBL] [Abstract][Full Text] [Related]
16. Subproteomic analysis of the cellular proteins associated with the 3' untranslated region of the hepatitis C virus genome in human liver cells.
Tingting P; Caiyun F; Zhigang Y; Pengyuan Y; Zhenghong Y
Biochem Biophys Res Commun; 2006 Sep; 347(3):683-91. PubMed ID: 16842740
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of damage-specific DNA binding protein 1 (DDB1) enhances the HBx-siRNA-mediated inhibition of HBV replication.
Tang KF; Xie J; Chen M; Liu Q; Zhou XY; Zeng W; Huang AL; Zuo GQ; Wang Y; Xiang R; Ren H
Biologicals; 2008 May; 36(3):177-83. PubMed ID: 18289873
[TBL] [Abstract][Full Text] [Related]
18. Serum-free cell culture system supplemented with lipid-rich albumin for hepatitis C virus (strain O of genotype 1b) replication.
Abe K; Ikeda M; Ariumi Y; Dansako H; Kato N
Virus Res; 2007 May; 125(2):162-8. PubMed ID: 17267063
[TBL] [Abstract][Full Text] [Related]
19. RNAi: a powerful tool to unravel hepatitis C virus-host interactions within the infectious life cycle.
Lupberger J; Brino L; Baumert TF
J Hepatol; 2008 Mar; 48(3):523-5. PubMed ID: 18192054
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic application of RNA interference for hepatitis C virus.
Watanabe T; Umehara T; Kohara M
Adv Drug Deliv Rev; 2007 Oct; 59(12):1263-76. PubMed ID: 17822803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
